DEFA14A: STAAR Surgical Reaffirms Alcon Merger Value

STAAR Surgical Company reiterates the compelling $28 per share cash value of its proposed merger with Alcon, highlighting significant premiums for stockholders.

Summary

• STAAR Surgical Company is reiterating the benefits of its proposed merger with Alcon.
• The merger offers STAAR stockholders $28 per share in cash.
• This represents a 51% premium to STAAR's closing stock price of $18.49 on August 4, 2025, the day before the agreement was announced.
• The offer also provides a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) as of August 4, 2025.
• The Board of Directors unanimously believes the merger is in the best interest of all STAAR stockholders.

Sentiment

Score: 8

Explanation: The filing strongly advocates for the merger, highlighting significant cash premiums for stockholders and addressing underlying business challenges that make the merger attractive. The tone is very positive regarding the merger's benefits for shareholders, despite acknowledging operational headwinds.

Positives

• Stockholders are expected to receive a compelling, premium cash value of $28 per share.
• The offer represents a 51% premium over the closing price on August 4, 2025.
• The offer represents a 59% premium over the 90-day VWAP as of August 4, 2025.
• The merger agreement includes provisions highly favorable to STAAR stockholders, extensively negotiated for value maximization.
• The cash value is believed to exceed what STAAR could achieve on a standalone basis in the foreseeable future.

Negatives

• STAAR faces a lower growth rate, impacting its standalone valuation.
• The company is exposed to substantial competitive and macro challenges in its markets.
• Heavy exposure to China, which is experiencing significant economic uncertainty and declining sales trends.

Risks

• Occurrence of any event, change, or circumstances that could terminate the merger agreement or extend its anticipated timetable.
• Failure to obtain approval of the proposed transaction from STAAR's stockholders.
• Failure to obtain required regulatory approvals or satisfy other closing conditions within expected timeframes or at all.
• Disruption of management's attention from ongoing business operations due to the proposed transaction.
• Impact of the announcement on STAAR's ability to retain and hire key personnel and maintain relationships with customers, suppliers, and others.
• Inability to meet expectations regarding the timing and completion of the transaction.
• Outcome of any legal proceedings instituted against STAAR related to the proposed transaction.
• Significant decline in STAAR's stock price if the proposed transaction is not consummated.
• Other important factors detailed in STAAR's Annual Report on Form 10-K for the year ended December 27, 2024, under "Risk Factors."

Future Outlook

The company believes the $28 per share cash value from the Alcon agreement surpasses what STAAR could achieve independently in the foreseeable future, citing lower growth rates and significant competitive and macroeconomic challenges, particularly in China.

Management Comments

• "The merger with Alcon provides STAAR stockholders with compelling, premium cash value, including a 51% premium to the closing price of STAAR common stock on August 4, 2025... and a 59% premium to STAARs 90-day Volume Weighted Average Price (VWAP) as of that date."
• "We believe the $28 per share cash value provided by the Alcon agreement exceeds what STAAR could achieve on a standalone basis in the foreseeable future, particularly, given STAARs lower growth rate and the resulting impact on its valuation, and the substantial competitive and macro challenges in the markets STAAR serves."
• "We look forward to engaging with our stockholders on the merits of the Alcon merger and why the STAAR Board of Directors unanimously believes it is in the best interest of all STAAR stockholders."

Industry Context

STAAR Surgical, a global leader in phakic IOLs (Implantable Collamer Lenses), is facing industry headwinds including competitive pressures and macroeconomic uncertainties, particularly in the crucial Chinese market where sales trends are declining. The proposed merger with Alcon, a major player in eye care, suggests a consolidation trend or a strategic exit for STAAR amidst these challenges, allowing its stockholders to realize immediate premium value rather than navigate future uncertainties independently.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other comparable companies, projects, or results regarding merger premiums or growth rates within the ophthalmic surgery industry. It only states that the $28 per share cash value is believed to exceed what STAAR could achieve on a standalone basis.

Legal Proceedings

• The filing mentions the risk of "the outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction," indicating potential future legal proceedings, but none are currently detailed as ongoing.

Stakeholder Impact

• Shareholders: Expected to receive a significant cash premium ($28 per share), representing a 51-59% premium, which the board believes is superior to standalone prospects.
• Employees: Risk of disruption to management's attention and impact on the ability to retain and hire key personnel due to the proposed transaction.
• Customers/Suppliers: Risk of impact on relationships with customers and suppliers due to the announcement.

Next Steps

• STAAR will file a definitive proxy statement on Schedule 14A with the SEC.
• Stockholders are urged to read all relevant documents filed or to be filed with the SEC, including the Proxy Statement, before making any voting decision.
• STAAR management looks forward to engaging with stockholders on the merits of the Alcon merger.
• Obtain stockholder approval for the proposed transaction.
• Obtain required regulatory approvals.
• Satisfy other closing conditions for the completion of the proposed transaction.

Key Dates

Recommendation

The proposed merger offers a substantial cash premium of 51% to the prior day's closing price and 59% to the 90-day VWAP, providing immediate and compelling value to stockholders. Management explicitly states this value exceeds what the company could achieve on a standalone basis given its lower growth rate and significant competitive and macro challenges, particularly in China. For existing shareholders, accepting this offer appears to be a financially sound decision, effectively a "strong buy" on the offer price.

Keywords

STAAR Surgical, Alcon, Merger, Acquisition, STAA, Ophthalmic, EVO ICL, Implantable Collamer Lenses, Vision Correction, SEC Filing, Proxy Statement, Cash Value, Premium